

PHARMACY POLICY STATEMENT

Mississippi Medicaid

DRUG NAME	Rituximab (Rituxan, Truxima, Ruxience, Riabni)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Rituximab, originally approved as Rituxan in 1997, is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process.

Rituximab will be considered for coverage when the following criteria are met:

Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

For **initial** authorization:

1. Member is at least 2 years of age; AND
2. Medication must be prescribed by or in consultation with a nephrologist or rheumatologist; AND
3. Member has a diagnosis of GPA or MPA; AND
4. Rituximab will be initiated in combination with glucocorticoids; AND
5. If the request is for a non-preferred product, member has had a trial of a preferred product where applicable, or acceptable clinical reason must be provided as to why it cannot be used. See Appendix A for named preferred and non-preferred products.
6. **Dosage allowed/Quantity limit:** IV infusion
Adult induction: 375 mg/m² once weekly for 4 weeks
Adult maintenance: Two 500 mg infusions separated by 2 weeks, then 500 mg every 6 months
Peds induction: 375 mg/m² once weekly for 4 weeks
Peds Maintenance: Two 250 mg/m² infusions separated by 2 weeks, then 250 mg/m² every 6 months

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes demonstrate clinical improvement of disease signs and symptoms.

If all the above requirements are met, the medication will be approved for an additional 12 months.

Pemphigus Vulgaris (PV)

For **initial** authorization:

1. Member is 18 years old or older; AND
2. Must be prescribed by or in consultation with a dermatologist; AND
3. Member has a documented diagnosis of moderate to severe PV; AND
4. Rituximab will be initiated in combination with a corticosteroid taper (unless contraindicated); AND

5. If the request is for a non-preferred product, member has had a trial of a preferred product where applicable, or acceptable clinical reason must be provided as to why it cannot be used. See Appendix A for named preferred and non-preferred products.
6. **Dosage allowed/Quantity limit:** Initial: Two 1000mg doses separated by 2 weeks; Maintenance: 500mg infusion at month 12 and every 6 months thereafter or based on clinical evaluation. Relapse: 1000mg infusion. Subsequent infusions may be administered no sooner than 16 weeks following the previous infusion.

If all the above requirements are met, the medication will be approved for 12 months.

For **reauthorization**:

1. Chart notes demonstrate clinical improvement of signs and symptoms (e.g. healed lesions, fewer new lesions, etc.)

If all the above requirements are met, the medication will be approved for an additional 12 months.

Rheumatoid Arthritis (RA)

For **initial** authorization:

1. Member is 18 years old or older; AND
2. Medication is being prescribed by or in consultation with a rheumatologist; AND
3. Member has a documented diagnosis of moderately- to severely- active RA; AND
4. Rituximab is being used in combination with methotrexate, or another non-biologic DMARD if unable to tolerate methotrexate; AND
5. Member must have inadequate response or intolerance to **ONE** or more tumor necrosis factor (TNF) antagonists (e.g. adalimumab, etanercept, infliximab) for at least 3 months each. Note: TNF antagonists require prior authorization; AND
6. If the request is for a non-preferred product, member has had a trial of a preferred product where applicable, or acceptable clinical reason must be provided as to why it cannot be used. See Appendix A for named preferred and non-preferred products.
7. **Dosage allowed/Quantity limit:** Two 1000mg doses separated by 2 weeks; subsequent courses repeated no sooner than every 16 weeks (every 24 weeks is typical).

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes demonstrate improvement of RA signs and symptoms (e.g. fewer number of painful and swollen joints, achievement of remission, etc.)

If all the above requirements are met, the medication will be approved for an additional 12 months.

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

For **initial** authorization:

1. Member is at least 12 years of age; AND

2. Medication must be prescribed by or in consultation with a hematologist; AND
3. Member has a presumptive or confirmed diagnosis of aTTP including **ALL** of the following:
 - a) Lab results showing thrombocytopenia (platelet count less than 100,000)
 - b) Microangiopathic hemolytic anemia (MAHA) confirmed by presence of schistocytes on blood smear
 - c) Testing shows an ADAMTS13 activity level less than 20% (20 IU/dL); OR
 - d) ADAMTS13 test has been ordered and results are pending AND
 - e) Documentation of a PLASMIC score of 6-7 (high risk) OR a FRENCH score of 2-3; AND
4. Rituximab was initiated in addition to plasma exchange and glucocorticoid; AND
5. If the request is for a non-preferred product, member has had a trial of a preferred product where applicable, or acceptable clinical reason must be provided as to why it cannot be used. See Appendix A for named preferred and non-preferred products.
6. **Dosage allowed/Quantity limit:** 375mg/m² once weekly for 4 doses (off label).

If all the above requirements are met, the medication will be approved for 30 days.

For **reauthorization**:

1. Member is experiencing a relapse of symptoms (thrombocytopenia and MAHA); AND
2. ADAMTS13 activity is less than 20% (lab report required).

If all the above requirements are met, the medication will be approved for an additional 30 days.

Neuromyelitis Optica Spectrum Disorder (NMOSD)

For **initial** authorization:

1. Member is 18 years old or older; AND
2. Medication must be prescribed by or in consultation with a neurologist; AND
3. Member has a diagnosis of NMOSD and is seropositive for aquaporin-4 (AQP4) IgG antibodies (documentation required); AND
4. If the request is for a non-preferred product, member has had a trial of a preferred product where applicable, or acceptable clinical reason must be provided as to why it cannot be used. See Appendix A for named preferred and non-preferred products.
5. **Dosage allowed/Quantity limit:** 1g on day 1 and day 15, then 1g every 6 months (off label)

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes must document disease stabilization, symptom improvement, and/or reduced frequency of relapses.

If all the above requirements are met, the medication will be approved for an additional 12 months.

Generalized Myasthenia Gravis (gMG)

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consultation with a neurologist; AND
3. Member meets **ONE** of the following:
 - a) Member has a documented diagnosis of gMG that is seropositive for MuSK antibodies AND has tried and failed corticosteroid treatment with or without a non-steroid immunosuppressant
 - b) Member has a documented diagnosis of refractory gMG that is seropositive for AChR antibodies AND has tried and failed ALL of the following: pyridostigmine, corticosteroid, and at least 1 non-steroid immunosuppressive (e.g., azathioprine, mycophenolate mofetil, tacrolimus); AND
4. If the request is for a non-preferred product, member has had a trial of a preferred product where applicable, or acceptable clinical reason must be provided as to why it cannot be used. See Appendix A for named preferred and non-preferred products.
5. **Dosage allowed/Quantity limit:** Consult updated clinical literature for recommendations. A variety of regimens have shown efficacy. (Off label use)

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes must document clinically meaningful improvement in symptom severity and functioning compared to previous treatment.

If all the above requirements are met, the medication will be approved for an additional 12 months.

Multiple Sclerosis (MS)

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consultation with a neurologist; AND
3. Member has a diagnosis of MS, including documentation of baseline relapse rate, lesion count, and/or disability status (e.g., EDSS); AND
4. Member has documentation of **ONE** of the following:
 - a) For primary progressive MS (PPMS): Trial and failure of Ocrevus
 - b) For relapsing forms of MS (RMS): Trial and failure of at least 2 preferred disease-modifying drugs indicated for MS; AND
5. Rituximab will not be used concurrently with another disease-modifying drug for MS; AND
6. If the request is for a non-preferred product, member has had a trial of a preferred product where applicable, or acceptable clinical reason must be provided as to why it cannot be used. See Appendix A for named preferred and non-preferred products.
7. **Dosage allowed/Quantity limit:** Consult updated clinical literature for recommendations. (Off label use)

If all the above requirements are met, the medication will be approved for 6 months.

For reauthorization:

1. Chart notes must indicate a positive clinical response such as lower relapse rate compared to baseline (i.e., for RMS) or overall stability of disease (i.e., for PPMS).

If all the above requirements are met, the medication will be approved for an additional 12 months.

Immune Thrombocytopenia (ITP)**For initial authorization:**

1. Medication is prescribed by or in consultation with a hematologist; AND
2. Member has a documented diagnosis of ITP of at least 6 months duration; AND
3. Member's platelet count is $<30 \times 10^9$ OR $<50 \times 10^9$ with active symptomatic bleeding or high risk factors for bleeding; AND
4. Member has had an insufficient response to **ONE** of the following:
 - a) Corticosteroid
 - b) Immunoglobulin
 - c) Splenectomy; AND
5. Member has had an insufficient response to a thrombopoietin receptor agonist (TPO-RA) such as Promacta, Nplate, or Doptelet; AND
6. Rituximab will not be used in combination with a TPO-RA or Tavalisse; AND
7. If the request is for a non-preferred product, member has had a trial of a preferred product where applicable, or acceptable clinical reason must be provided as to why it cannot be used. See Appendix A for named preferred and non-preferred products.
8. **Dosage allowed/Quantity limit:** Consult updated clinical literature for recommendations. Example (Off-label): 4 weekly doses of 375 mg/m^2

If all the above requirements are met, the medication will be approved for 30 days.

For reauthorization:

1. Chart notes must document clinically significant improvement in platelet count compared to baseline following a course of rituximab; AND
2. Patient has a relapse of symptoms and meets all initial criteria.

If all the above requirements are met, the medication will be approved for an additional 30 days .

Non-Hodgkin's Lymphoma (NHL)

These requests must be submitted through [NantHealth/Eviti](#) portal.

Chronic Lymphocytic Leukemia (CLL)

These requests must be submitted through [NantHealth/Eviti](#) portal.

Appendix A:

Preferred Products	Non-preferred Products
• Ruxience • Truxima	• Rituxan • Riabni

TrueCare considers Rituximab not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
08/20/2013	Change in diagnosis
07/15/2014	Added diagnosis TTP and additional criteria to CD20+ CLL
07/15/2015	Added MCG 19th edition criteria
10/04/2016	Change in diagnoses to FDA approved uses, updated references with supporting guidelines and literature
06/09/2020	Transferred policy to new template, indicated Eviti carve-outs. Revised criteria for vasculitis diagnoses (GPA, MPA); previously listed as ANCA vasculitis – updated age, specified trial for non-severe, simplified the cyclophosphamide trial language. Revised criteria for Rheumatoid Arthritis – changed from trial of 2 TNF to 1 TNF. Added new diagnosis Pemphigus Vulgaris and its criteria
07/28/2020	Added criteria for aTTP.
10/13/2020	Added criteria for NMOSD. For RA, stated they must use another DMARD if they can't use MTX.
02/09/2022	Transferred to new template. RA: Added new reference. GPA/MPA: Added references and made updates per new guidelines. Added MMF to #3. Removed requirement for trial/failure of cyclophosphamide. PV: Added new references. Removed required trial/failure of steroid and adjuvant immunosuppressant. Added new section for myasthenia gravis (off label).
07/27/2022	Added new section for multiple sclerosis (off label).
02/21/2023	Renamed policy as Rituximab and added biosimilars. Added section for off label treatment of ITP.
01/04/2024	Added appendix; added criteria to trial preferred product within policy when applicable; added references.
10/10/2024	GPA/MPA: Added dosing info. Updated references. Removed step for non-severe disease and removed differentiation between severe and non-severe (Hellmich 2022).
02/10/2026	aTTP: Updated references. Amended platelet count from 150,000 to 100,000. Changed PLASMIC score documentation to high risk only (6-7); added French score as an alternate option. Changed ADAMTS13 activity level requirement from less than 10% to less than 20% (ISTH guidelines). Lowered age limit from 18 to 12 years of age per Cablivi product label update so they can be used together. Removed criterion regarding non-response to PEX/steroid. Changed that it is being used with PEX/steroid to that it was started with PEX/steroid. ITP: Added reference. gMG: Updated references; changed from trial of 2 non-steroid immunosuppressives to 1 for seropositive cases (Jacob, WU).

1. Rituxan [package insert]. South San Francisco, CA: Genentech, Inc.; 2021.
2. Truxima [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2022.
3. Ruxience [package insert]. New York, NY : Pfizer Inc.; 2023.
4. Riabni [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2022.

5. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010; 363:221.
6. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomized trial. *Ann Rheum Dis* 2015; 74(6): 1178-1182.
7. Latimer NR, Carroll C, Wong R, et al. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal. *Pharmacoeconomics* 2014; 32(12): 1171-1183.
8. McGeoch L, Twilt M, Fomora L, et al. CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. *The Journal of Rheumatology*. 2015;43(1):97-120. doi:10.3899/jrheum.150376
9. Terrier B, Pagnoux C, Perrodeau É, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. *Annals of the Rheumatic Diseases*. 2018;77(8):1150-1156. doi:10.1136/annrheumdis-2017-212768
10. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021
11. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Arthritis Care Res (Hoboken)*. 2021;73(8):1088-1105. doi:10.1002/acr.24634
12. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. *Ann Rheum Dis*. 2024;83(1):30-47. Published 2024 Jan 2. doi:10.1136/ard-2022-223764
13. Singh JA, Saag KG, Bridges Jr. SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research* 2015: 1-25.
14. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? *Annals of the Rheumatic Diseases*. 2009;69(2):387-393. doi:10.1136/ard.2008.105064
15. Solau-Gervais E, Prudhomme C, Philippe P, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. *Joint Bone Spine*. 2012;79(3):281-284. doi:10.1016/j.jbspin.2011.05.002
16. Harrold LR, Reed GW, Magner R, et al. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. *Arthritis Research & Therapy*. 2015;17(1). doi:10.1186/s13075-015-0776-1
17. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. *Annals of the Rheumatic Diseases*. 2011;70(9):1575-1580. doi:10.1136/ard.2010.148759
18. Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. *Annals of the Rheumatic Diseases*. 2014;74(6):979-984. doi:10.1136/annrheumdis-2013-203993
19. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*. 2021;73(7):1108-1123. doi:10.1002/art.41752
20. Hertl M, Eming R. Management of refractory pemphigus vulgaris and pemphigus foliaceus. *UpToDate*. https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus?search=pemphigus%20vulgaris&source=search_result&selectedTitle=3~40&usage_type=default&display_rank=3. Updated March 5, 2020. Accessed June 11, 2020.
21. Heelan K, Al-Mohammed F, Smith MJ, et al. Durable Remission of Pemphigus With a Fixed-Dose Rituximab Protocol. *JAMA Dermatology*. 2014;150(7):703. doi:10.1001/jamadermatol.2013.6739
22. Murrell DF, Dick S, Ahmed A, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *Journal of the American Academy of Dermatology*. 2008;58(6):1043-1046. doi:10.1016/j.jaad.2008.01.012
23. Agarwal A, Hall RP, Bañez LL, Cardones AR. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. *Plos One*. 2018;13(9). doi:10.1371/journal.pone.0198074

24. Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. *J Am Acad Dermatol*. 2020;82(3):575-585.e1. doi:10.1016/j.jaad.2018.02.021
25. Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). *J Eur Acad Dermatol Venereol*. 2020;34(9):1900-1913. doi:10.1111/jdv.16752
26. Zhao W, Wang J, Zhu H, Pan M. Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies. *Clin Rev Allergy Immunol*. 2021;61(3):351-362. doi:10.1007/s12016-021-08882-1
27. ISTH Guideline for the Diagnosis and Management of Thrombotic Thrombocytopenic Purpura. https://cdn.ymaws.com/www.isth.org/resource/resmgr/guidance_and_guidelines/ttp_guideline/isth_ttp_guideline_september.pdf. Accessed 7/15/2020.
28. Zheng XL, Al-Housni Z, Cataland SR, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2025;23(11):3711-3732. doi:10.1016/j.jtha.2025.06.002
29. Scully M, Rayment R, Clark A, et al. A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. *Br J Haematol*. 2023;203(4):546-563. doi:10.1111/bjh.19026
30. Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. *Res Pract Thromb Haemost*. 2018;3(1):26-37. Published 2018 Nov 16. doi:10.1002/rth2.12160
31. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. *Blood*. 2011;118(7):1746-1753. doi:10.1182/blood-2011-03-341131
32. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura [published correction appears in *Blood*. 2017 Oct 5;130(14):1684]. *Blood*. 2015;125(25):3860-3867. doi:10.1182/blood-2014-11-551580
33. Kessler RA, Mealy MA, Levy M. Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic. *Curr Treat Options Neurol*. 2016;18(1):2. doi:10.1007/s11940-015-0387-9
34. Weinshenker B. Neuromyelitis Optica Spectrum Disorder. NORD (National Organization for Rare Disorders). <https://rarediseases.org/rare-diseases/neuromyelitis-optica/>. Published August 25, 2020. Accessed October 2, 2020.
35. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. *JAMA Neurol*. 2014;71(3):324-330. doi:10.1001/jamaneurol.2013.5699
36. Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. *Revue Neurologique*. 2018;174(4):255-264. doi:10.1016/j.neurol.2017.11.005
37. Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. *JAMA Neurol*. 2016;73(11):1342-1348. doi:10.1001/jamaneurol.2016.1637
38. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. *The Lancet Neurology*. 2020;19(4):298-306. doi:10.1016/s1474-4422(20)30066-1
39. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology*. 2021;96(3):114-122. doi:10.1212/WNL.00000000000011124
40. Rodolico C, Bonanno C, Toscano A, Vita G. MuSK-Associated Myasthenia Gravis: Clinical Features and Management. *Front Neurol*. 2020;11:660. Published 2020 Jul 23. doi:10.3389/fneur.2020.00660
41. Feng X, Song Z, Wu M, et al. Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. *Front Neurol*. 2021;12:725700. Published 2021 Dec 1. doi:10.3389/fneur.2021.725700
42. Young C, McGill SC. Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK571915/>
43. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790

44. Jacob S, Farrugia ME, Hewamadduma C, et al. Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update). *Pract Neurol*. 2025;25(5):422-437. Published 2025 Sep 12. doi:10.1136/pn-2025-004655
45. Wu J, Eriksson-Dufva A, Budzianowska A, et al. Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial. *Eur J Neurol*. 2025;32(11):e70418. doi:10.1111/ene.70418
46. National Multiple Sclerosis Society. The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence. A Consensus Paper by the Multiple Sclerosis Coalition; 2019. Available from: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf. Accessed August 18, 2021.
47. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. *Am J Med*. 2020;133(12):1380-1390.e2. doi:10.1016/j.amjmed.2020.05.049
48. Filippini G, Kruja J, Del Giovane C. Rituximab for people with multiple sclerosis. *Cochrane Database Syst Rev*. 2021;11(11):CD013874. Published 2021 Nov 8. doi:10.1002/14651858.CD013874.pub2
49. Alldredge B, Jordan A, Imitola J, Racke MK. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center. *Clin Neuropharmacol*. 2018;41(2):56-59. doi:10.1097/WNF.0000000000000268
50. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020 Jan 28;4(2):252]. *Blood Adv*. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966
51. Provan D, Arnold DM, Bussell JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv*. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812
52. Neunert CE, Arnold DM, Grace RF, Kuhne T, McCrae KR, Terrell DR. The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. *Blood Adv*. 2024;8(13):3578-3582. doi:10.1182/bloodadvances.2023012541

Effective date: 07/01/2026

Revised date: 02/10/2026